Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings

Michelle T. Martin; Sonalie Patel; Laura Kulik; Christine Chan

doi:10.1016/j.jhep.2021.02.024

Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings

Michelle T. Martin^*, Sonalie Patel, Laura Kulik, Christine Chan

^*Corresponding author for this work

Medicine, Hepatology Division

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English (US)
Pages (from-to)	251-254
Number of pages	4
Journal	Journal of Hepatology
Volume	75
Issue number	1
DOIs	https://doi.org/10.1016/j.jhep.2021.02.024
State	Published - Jul 2021

Funding

CC does not have any conflicts of interest to disclose. LK serves on the advisory board for Bayer, Eisai, Exelixis, Genentech, Gilead and Merck; is on the speakers’ bureau for Bayer, Gilead and Peer View CME; and is a researcher for Target-HCC. MM serves on the speakers’ bureau for AbbVie, has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead, and Merck stock. SP serves on the speakers’ bureau for AbbVie.

Keywords

direct-acting antivirals
glecaprevir/pibrentasvir
hepatitis C virus
retreatment
ribavirin
salvage therapy
sofosbuvir

ASJC Scopus subject areas

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jhep.2021.02.024

Cite this

@article{cb92649fe5a94231a2d042d4660e0b19,

title = "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings",

keywords = "direct-acting antivirals, glecaprevir/pibrentasvir, hepatitis C virus, retreatment, ribavirin, salvage therapy, sofosbuvir",

author = "Martin, {Michelle T.} and Sonalie Patel and Laura Kulik and Christine Chan",

note = "Funding Information: CC does not have any conflicts of interest to disclose. LK serves on the advisory board for Bayer, Eisai, Exelixis, Genentech, Gilead and Merck; is on the speakers{\textquoteright} bureau for Bayer, Gilead and Peer View CME; and is a researcher for Target-HCC. MM serves on the speakers{\textquoteright} bureau for AbbVie, has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead, and Merck stock. SP serves on the speakers{\textquoteright} bureau for AbbVie. ",

year = "2021",

month = jul,

doi = "10.1016/j.jhep.2021.02.024",

language = "English (US)",

volume = "75",

pages = "251--254",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings

AU - Martin, Michelle T.

AU - Patel, Sonalie

AU - Kulik, Laura

AU - Chan, Christine

N1 - Funding Information: CC does not have any conflicts of interest to disclose. LK serves on the advisory board for Bayer, Eisai, Exelixis, Genentech, Gilead and Merck; is on the speakers’ bureau for Bayer, Gilead and Peer View CME; and is a researcher for Target-HCC. MM serves on the speakers’ bureau for AbbVie, has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead, and Merck stock. SP serves on the speakers’ bureau for AbbVie.

PY - 2021/7

Y1 - 2021/7

KW - direct-acting antivirals

KW - glecaprevir/pibrentasvir

KW - hepatitis C virus

KW - retreatment

KW - ribavirin

KW - salvage therapy

KW - sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=85107310155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107310155&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2021.02.024

DO - 10.1016/j.jhep.2021.02.024

M3 - Letter

C2 - 33652031

AN - SCOPUS:85107310155

SN - 0168-8278

VL - 75

SP - 251

EP - 254

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 1

ER -

Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this